MX2021007019A - Derivados de xantina sustituida. - Google Patents

Derivados de xantina sustituida.

Info

Publication number
MX2021007019A
MX2021007019A MX2021007019A MX2021007019A MX2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A
Authority
MX
Mexico
Prior art keywords
xanthine derivatives
substituted xanthine
formula
substituted
trpc5
Prior art date
Application number
MX2021007019A
Other languages
English (en)
Spanish (es)
Inventor
Kai Gerlach
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021007019A publication Critical patent/MX2021007019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021007019A 2018-12-12 2019-12-10 Derivados de xantina sustituida. MX2021007019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
MX2021007019A true MX2021007019A (es) 2021-09-10

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007019A MX2021007019A (es) 2018-12-12 2019-12-10 Derivados de xantina sustituida.

Country Status (18)

Country Link
US (2) US11198696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7502299B2 (cg-RX-API-DMAC7.html)
KR (1) KR102877857B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166151B (cg-RX-API-DMAC7.html)
AU (1) AU2019396499B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008316A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001509A1 (cg-RX-API-DMAC7.html)
DK (1) DK3894410T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2964630T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064908T2 (cg-RX-API-DMAC7.html)
IL (1) IL283768B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007019A (cg-RX-API-DMAC7.html)
PH (1) PH12021551345A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894410T3 (cg-RX-API-DMAC7.html)
TW (1) TWI825243B (cg-RX-API-DMAC7.html)
WO (1) WO2020120450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370372B (es) 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP7114702B2 (ja) * 2017-07-11 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換キサンチン誘導体
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted

Also Published As

Publication number Publication date
PL3894410T3 (pl) 2024-03-18
HUE064908T2 (hu) 2024-04-28
ES2964630T3 (es) 2024-04-08
BR112021008316A2 (pt) 2021-08-03
KR20210102955A (ko) 2021-08-20
US11198696B2 (en) 2021-12-14
CN113166151A (zh) 2021-07-23
DK3894410T3 (da) 2023-11-27
IL283768A (en) 2021-07-29
CN113166151B (zh) 2023-12-01
TWI825243B (zh) 2023-12-11
JP7502299B2 (ja) 2024-06-18
CA3119229A1 (en) 2020-06-18
KR102877857B1 (ko) 2025-10-29
EP3894410B1 (en) 2023-10-11
EP3894410A1 (en) 2021-10-20
TW202039495A (zh) 2020-11-01
US20200190093A1 (en) 2020-06-18
IL283768B1 (en) 2024-01-01
US20220177479A1 (en) 2022-06-09
WO2020120450A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
PH12021551345A1 (en) 2022-05-11
AU2019396499A1 (en) 2021-05-27
AU2019396499B2 (en) 2024-10-10
IL283768B2 (en) 2024-05-01
JP2022512373A (ja) 2022-02-03
EA202191588A1 (ru) 2021-10-18

Similar Documents

Publication Publication Date Title
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CO2020007244A2 (es) Inhibidores de kras g12c
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
CY1123263T1 (el) Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CO2019015102A2 (es) Nuevos derivados de xantina sustituidos
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CL2021001509A1 (es) Derivados de xantina sustituida
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
MX2019014845A (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
UY37084A (es) Derivados de indano y su uso en terapias
BR112021018266A2 (pt) Composições e métodos para tratar formas positivas de receptor andrógeno de câncer
BR112019021330A2 (pt) Métodos e compostos terapêuticos.